Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society-Reference-Cited by-同舟云学术

Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society

Published:2024-02-15 Issue:7 Volume:30 Page:899-924
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Collongues Nicolas¹²³⁴^ORCID,Durand-Dubief Françoise⁵,Lebrun-Frenay Christine⁶⁷,Audoin Bertrand⁸^ORCID,Ayrignac Xavier⁹¹⁰¹¹^ORCID,Bensa Caroline¹²,Bigaut Kévin¹³^ORCID,Bourre Bertrand¹³,Carra-Dallière Clarisse⁹,Ciron Jonathan¹⁴¹⁵^ORCID,Defer Gilles¹⁶,Kwiatkowski Arnaud¹⁷,Leray Emmanuelle¹⁸,Maillart Elisabeth¹⁹^ORCID,Marignier Romain⁵^ORCID,Mathey Guillaume²⁰,Morel Nathalie²¹,Thouvenot Eric²²²³^ORCID,Zéphir Hélène²⁴,Boucher Julie²⁵,Boutière Clémence²⁶,Branger Pierre²⁷,Da Silva Angélique²⁸,Demortière Sarah⁸,Guillaume Maxime¹³,Hebant Benjamin¹³,Januel Edouard²⁹³⁰^ORCID,Kerbrat Anne³¹³²,Manchon Eric³³,Moisset Xavier³⁴^ORCID,Montcuquet Alexis³⁵,Pierret Chloé³⁶,Pique Julie⁵,Poupart Julien³⁷,Prunis Chloé²⁰,Roux Thomas³⁸³⁹^ORCID,Schmitt Perrine²²,Androdias Géraldine⁴⁰⁴¹,Cohen Mikael⁴²^ORCID

Affiliation:

1. Department of Neurology, University Hospital of Strasbourg, Strasbourg, France

2. Center for Clinical Investigation, INSERM U1434, Strasbourg, France

3. Biopathology of Myelin, Neuroprotection and Therapeutic Strategy, INSERM U1119, Strasbourg, France

4. Department of Pharmacology, Addictology, Toxicology, and Therapeutics, Strasbourg University, Strasbourg, France

5. Service de Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Bron, France

6. Department of Neurology, CHU Nice, Nice, France

7. Université Côte d’Azur, UMR2CA-URRIS, Nice, France

8. Department of Neurology, CRMBM, APHM, Aix-Marseille University, Marseille, France

9. Department of Neurology, Montpellier University Hospital, Montpellier, France

10. University of Montpellier, Montpellier, France

11. INM, INSERM, Montpellier, France

12. Department of Neurology, Hôpital Fondation Adolphe de Rothschild, Paris, France

13. Department of Neurology, CHU Rouen, Rouen, France

14. CHU de Toulouse, CRC-SEP, Department of Neurology, Toulouse, France

15. Université Toulouse III, Infinity, INSERM UMR1291—CNRS UMR5051, Toulouse, France

16. Department of Neurology, Caen University Hospital, Caen, France

17. Department of Neurology, Lille Catholic University, Lille Catholic Hospitals, Lille, France

18. Université de Rennes, EHESP, CNRS, INSERM, ARENES-UMR 6051, RSMS-U1309, Rennes, France

19. Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France

20. Department of Neurology, Nancy University Hospital, Nancy, France

21. Service de Neurologie, Centre Hospitalier Annecy Genevois, Epagny-Metz-Tessy, France

22. Service de Neurologie, CHU de Nîmes, Nîmes, France

23. Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, Montpellier, France

24. University of Lille, INSERM U1172, CHU de Lille, Lille, France

25. Department of Neurology, CHU de Lille, Lille, France

26. Department of Neurology, University Hospital of Marseille, Marseille, France

27. Service de Neurologie, CHU de Caen Normandie, Caen, France

28. Breast Cancer Unit, Centre François Baclesse, Institut Normand du Sein, Caen, France

29. Sorbonne Université, Paris, France/Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Paris, France

30. Département de Neurologie, Hôpital Pitié Salpêtrière, AP-HP, Paris, France

31. Service de Neurologie, CHU de Rennes, France

32. EMPENN U1228, INSERM-INRIA, Rennes, France

33. Service de Neurologie, Centre Hospitalier de Gonesse, Gonesse, France

34. Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, Neuro-Dol, Clermont-Ferrand, France

35. Department of Neurology, CHU of Bordeaux, Bordeaux, France

36. Université de Rennes, EHESP, CNRS, INSERM, ARENES-UMR 6051, RSMS U-1309, Rennes, France

37. Department of Neurology and U995-LIRIC-Lille Inflammation Research International Center, INSERM, University of Lille, CHU Lille, Lille, France

38. Hôpital La Pitié-Salpêtrière, Service de Neurologie, Paris, France

39. CRC-SEP Paris. Centre des maladies inflammatoires rares du cerveau et de la moelle de l’enfant et de l’adulte (Mircem)

40. Service de Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Bron, France

41. Clinique de la Sauvegarde–Ramsay Santé, Lyon, France

42. Department of Neurology, CHU Nice, Nice, France/Université Côte d’Azur, UMR2CA-URRIS, Nice, France

Abstract

Background: Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms of cancer risk. Objective: To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS). Methods: The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal. Results: Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations. Conclusion: These recommendations propose a strategic approach to managing cancer risk in PwMS.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/13524585231223880

Reference207 articles.

1. Casey R. Epidemiology of multiple sclerosis in France. OFSEP database, 2023, https://www.ofsep.org/fr/la-cohorte-ofsep/descriptif-de-la-cohorte.

2. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba

3. The changing face of multiple sclerosis: Prevalence and incidence in an aging population

4. Etiology, effects and management of comorbidities in multiple sclerosis: recent advances

5. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial